ArticlePoultry science2026
Sulfated chitooligosaccharide selenium alleviates deoxynivalenol-induced intestinal injury in neonatal chicken through modulation of ULK1/LC3-mediated autophagy.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deoxynivalenol (DON) disrupts intestinal epithelial integrity through oxidative stress and dysregulated autophagy. This study evaluates the efficacy of sulfated chitooligosaccharide selenium (S-COS-Se) in protecting chicken embryos and intestinal epithelial cells from DON-induced intestinal injury. Five hundred 9-day-old embryonated eggs were allocated into 10 groups: Control, Na₂SeO₃, chitosan sulfate, chitosan-selenium, S-COS-Se, DON, and 4 combination groups. Additionally, intestinal epithelial cells were treated with DON alone or combined with various selenium formulations for 24 h. S-COS-Se co-treatment alleviated DON-induced cytotoxicity and restored cell viability while preserving epithelial morphology. S-COS-Se modulated autophagy through PI3K restoration, ULK1 suppression, and LC3-II/LC3-I ratio normalization with reduced p62 accumulation. Transmission electron microscopy confirmed intact mitochondrial cristae and reduced autophagic vacuoles. S-COS-Se attenuated oxidative stress by decreasing levels of malondialdehyde, hydroxyl free radical, and hydrogen peroxide, while enhancing antioxidant enzyme activities. It also restored immune homeostasis through elevated immunoglobulins and suppressed pro-inflammatory cytokines, exhibiting superior efficacy over other selenium compounds. These findings demonstrate that S-COS-Se confers broad protection against DON toxicity by the integrated modulation of ULK1/LC3-mediated autophagy, antioxidant defense, and immune homeostasis. This novel organoselenium compound has potential as a feed additive in poultry diets to protect against mycotoxin-induced intestinal injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.